Triple-marker test as screening for down syndrome: A meta-analysis

Obstetrical and Gynecological Survey

Volumn 53, Issue 6, 1998, Pages 369-376

  Conde Agudelo, Agustin ^a,b   Kafury Goeta, Ana C ^a  

^a Dept of Obstetrics and Gynecology   (Colombia)

^b NONE   (Colombia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; BIOCHEMICAL MARKER; CHORIONIC GONADOTROPIN; ESTRIOL;

ADULT; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DOWN SYNDROME; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MATERNAL AGE; META ANALYSIS; PRENATAL DIAGNOSIS; RECEIVER OPERATING CHARACTERISTIC; REVIEW; SCREENING TEST;

ADULT; DOWN SYNDROME; FALSE POSITIVE REACTIONS; FEMALE; HUMANS; MASS SCREENING; MATERNAL AGE; PREGNANCY; PREGNANCY, HIGH-RISK; PRENATAL DIAGNOSIS; SENSITIVITY AND SPECIFICITY;

EID: 0031834824     PISSN: 00297828     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006254-199806000-00022     Document Type: Review

References (67)

1. Wald NJ, Cuckle HS, Densem JW et al. Maternal serum screening for Down's syndrome in early pregnancy. Br Med J 1988;297:883.
2. Irwig L, Tosteson ANA, Gatsonis C et al. Guidelines for meta-analyses evaluating diagnostic tests. Ann Intern Med 1994; 120:667.
3. Moses LE, Shapiro D, Littenberg B. Combining independent studies of a diagnostic test into a summary ROC curve: Data-analytic approaches and some additional considerations. Stat Med 1993;12:1293.
4. Feinstein AR. Clinical epidemiology: The architecture of clinical research. Philadelphia: WB Saunders, 1985, pp 601.
5. Sackett DL, Haynes RB, Guyatt GH et al. Clinical Epidemiology: A Basic Science for Clinical Medicine, 2nd Ed. Boston: Little Brown, 1991, pp. 117.
6. Mancini G, Perona M, Dall'Amico D et al. Screening for fetal Down's syndrome with maternal serum markers - An experience in Italy. Prenat Diagn 1991;11:245.
7. Haddow JE, Palomaki GE, Knight GJ et al. Prenatal screening for Down's syndrome with use of maternal serum markers. N Engl J Med 1992;327:588.
8. Phillips OP, Elias S, Shulman LP et al. Maternal serum screening for fetal Down syndrome in women less than 35 years of age using alpha-fetoprotein, hCG, and unconjugated estriol: A prospective 2-year study. Obstet Gynecol 1992;80:353.
9. Wald N, Kennard A, Densem JW et al. Antenatal maternal serum screening for Down's syndrome: Results of a demonstration project. Br Med J 1992;305:391.
10. Crandall BF, Hanson FW, Keener S et al. Maternal serum screening for α-fetoprotein, unconjugated estriol, and human chorionic gonadotropin between 11 and 15 weeks of pregnancy to detect fetal chromosome abnormalities. Am J Obstet Gynecol 1993;168:1864.
11. Burton BK, Prins GS, Verp MS. A prospective trial of prenatal screening for Down syndrome by means of maternal serum α-fetoprotein, human chorionic gonadotropin, and unconjugated estriol. Am J Obstet Gynecol 1993;169:526.
12. Cheng E, Luthy DA, Zebelman AM et al. A prospective evaluation of a second-trimester screening test for fetal Down syndrome using maternal serum alpha-fetoprotein, hCG, and unconjugated estriol. Obstet Gynecol 1993;81:72.
13. Wenstrom KD, Williamson RA, Grant SS et al. Evaluation of multiple-marker screening for Down syndrome in a statewide population. Am J Obstet Gynecol 1993;169:793.
14. Zwahr C, Voss P, Kistner G. Nichtinvasiver serum-test (NIS) zur pranatalen erfassung von Morbus Down, anderen chromosomalen anomalien und offenen Neuralrohrdefekten-Eine prospektive studie. Geburtshilfe Frauenheilkd 1994;54:355.
15. Mancini G, Perona M, Dall'Amico D et al. Maternal serum markers. Estimation of the risk of Down's syndrome: a prospective study. Int J Clin Lab Res 1994;24:49.
16. Goodburn SF, Yates JR, Raggatt PR et al. Second-trimester maternal serum screening using alpha-fetoprotein, human chorionic gonadotropin, and unconjugated estriol: Experience of a regional program. Prenat Diagn 1994;14:391.
17. Haddow JE, Palomaki GE, Knight GJ et al. Reducing the need for amniocentesis in women 35 years of age or older with serum markers for screening. N Engl J Med 1994;330:1114.
18. Bradley LA, Horwitz JA, Dowman AC et al. Triple marker screening for fetal Down's syndrome. Int Pediatr 1994;9:168.
19. Zimmermann R, Schmid W, Binkert F et al. Trisomie-21-Screening mit AFPplus in der ostlichen landeshalfte der Schweiz. Schweiz Med Wochenschr 1995;125:1286.
20. Verloes A, Schoos R, Herens C et al. A prenatal trisomy 21 screening program using α-fetoprotein, human chorionic gonadotropin, and free estriol assays on maternal dried blood. Am J Obstet Gynecol 1995;172:167.
21. Kellner LH, Weiss RR, Weiner Z et al. The advantages of using triple-marker screening for chromosomal abnormalities. Am J Obstet Gynecol 1995;172:831.
22. Wenstrom KD, Desai R, Owen J et al. Comparison of multiple-marker screening with amniocentesis for the detection of fetal aneuploidy in women 35 years old. Am J Obstet Gynecol 1995;173:1287.
23. McDuffie RS Jr, Haverkamp AD, Starck CF et al. Prenatal screening using maternal serum alpha-fetoprotein, human chorionic gonadotropin, and unconjugated estriol: Two-year experience in a health maintenance organization. J Maternal Fetal Med 1996;5:70.
24. Valerio D, Aiello R, Altieri V et al. Maternal serum screening of fetal chromosomal abnormalities by AFP, UE3, hCG and free-beta hCG. Prospective and retrospective results. Minerva Ginecol 1996;48:169.
25. Benn PA, Home D, Craffey A et al. Maternal serum screening for birth defects: Results of a Connecticut regional program. Conn Med 1996;60:322.
26. Nørgaard-Pedersen B, Larsen SO, Arends J et al. Maternal serum markers in screening for Down syndrome. Clin Genet 1990;37:35.
27. Heyl PS, Miller W, Canick JA. Maternal serum screening for aneuploid pregnancies by alpha-fetoprotein, hCG, and unconjugated estriol. Obstet Gynecol 1990;76:1025.
28. MacDonald ML, Wagner RM, Slotnick RN. Sensitivity and specificity of screening for Down syndrome with alpha-fetoprotein, hCG, unconjugated estriol, and maternal age. Obstet Gynecol 1991;77:63.
29. Muller U, Benz R, Krahner-Pilat M et al. Pranatales Serum-screening auf Down-Syndrom. Z Geburtshilfe Perinatol 1992; 196:129.
30. Lemay C, Roussel-Mizon N, Thepot F et al. Maternal serum screening for fetal Down's syndrome: A retrospective study. Clin Chim Acta 1995;238:151.
31. Reynolds TM, Nix AB, Dunstan FD et al. Age-specific detection and false-positive rates: An aid to counseling in Down syndrome risk screening. Obstet Gynecol 1993;81:447.
32. Dick PT. Periodic health examination, 1996 update: 1. Prenatal screening for and diagnosis of Down syndrome. Canadian Task Force on the Periodic Health Examination. Can Med Assoc J 1996;154:465.
33. Loncar J, Barnabei VM, Larsen JW Jr. Advent of maternal serum markers for Down syndrome screening. Obstet Gynecol Surv 1995;50:316.
34. Pescia G, Dao MH, Weihs D et al. Le triple depistage de la trisomie 21: Resultats prospectifs de 7039 evaluations. Rev Med Suisse Romande 1993;113:277.
35. Holzgreve W, Schloo R, Veress L et al. Moglichkeiten der modifizierung der rizikoangaben fur chromosomenstorungen-Vorteile der sog. "Triple"-Marker-Untersuchungen im Vergleich zum reinen "Altersscreening." Zentralbl Gynakol 1994; 116:643.
36. Thornton JG, Cartmill RS, Williams J et al. Clinical experience with the triple test for Down's syndrome screening. J Perinat Med 1991;19:151.
37. Shoat M, Legum C, Romem Y et al. Down syndrome prevention program in a population with an older maternal age. Obstet Gynecol 1995;85:368.
38. Benn PA, Home D, Briganti S et al. Prenatal diagnosis of diverse chromosome abnormalities in a population of patients identified by triple-marker testing as screen positive for Down syndrome. Am J Obstet Gynecol 1995;173:496.
39. Cuckle HS, Wald NJ, Thompson SG. Estimating a woman's risk of having a pregnancy associated with Down's syndrome using her age and serum alpha-fetoprotein level. Br J Obstet Gynaecol 1987;94:387.
40. Begg CB. Biases in the assessment of diagnostic tests. Stat Med 1987;6:411.
41. Johnson AM, Palomaki GE, Haddow JE. Maternal serum alpha-fetoprotein levels in pregnancies among black and white women with fetal open spina bifida: A United States collaborative study. Am J Obstet Gynecol 1990;162:328.
42. Crandall BF, Lebherz TB, Sehroth PC et al. Alpha-fetoprotein concentrations in maternal serum: Relation to race and body weight. Clin Chem 1983;29:531.
43. Kulch P, Keener S, Matsumoto M et al. Racial differences in maternal serum human chorionic gonadotropin and unconjugated estriol levels. Prenat Diagn 1993;13:191.
44. Muller F, Bussieres L, Pelissier MC et al. Do racial differences exist in second-trimester maternal hCG levels? A study of 23,369 patients. Prenat Diagn 1994;14:633.
45. Johnson AM, Palomaki GE, Haddow JE. The effect of adjusting maternal serum alpha-fetoprotein levels for maternal weight in pregnancies with fetal open spina bifida: A United States collaborative study. Am J Obstet Gynecol 1990;163:9.
46. Wenstrom KD, Owen J, Boots L et al. The influence of maternal weight on human chorionic gonadotropin in the multiple-marker screening test for fetal Down syndrome. Am J Obstet Gynecol 1995;173:1297.
47. Bartels I, Hoppe-Sievert B, Bockel B et al. Adjustment formulae for maternal serum alpha-fetoprotein, human chorionic gonadotropin, and unconjugated estriol to maternal weight and smoking. Prenat Diagn 1993;13:123.
48. Reynolds TM, Penney MD, Hughes H et al. The effect of weight correction on risk calculations for Down's syndrome screening. Ann Clin Biochem 1991;28:245.
49. Wald NJ, Cuckle HS, Boreham J et al. Maternal serum alpha-fetoprotein and diabetes mellitus. Br J Obstet Gynaecol 1979; 86:101.
50. Milunsky A, Alpert E, Kitzmiller JL et al. Prenatal diagnosis of neural tube defects. VIII. The importance of alpha-fetoprotein screening in diabetic pregnant women. Am J Obstet Gynecol 1982;142:1030.
51. Wald NJ, Cuckle HS, Densem JW et al. Maternal serum unconjugated oestriol and human chorionic gonadotropin levels in pregnancies with insulin-dependent diabetes: Implications for screening for Down's syndrome. Br J Obstet Gynaecol 1992;99:51.
52. Palomaki GE, Knight GJ, Haddow GE et al. Cigarette smoking and levels of maternal serum alpha-fetoprotein, unconjugated estriol, and hCG: Impact on Down syndrome screening. Obstet Gynecol 1993;81:675.
53. Mooney RA, Arvan DA, Saller DN Jr et al. Decreased maternal serum hCG levels with increasing gravidity and parity. Obstet Gynecol 1995;86:900.
54. Haddow JE, Palomaki GE, Knight GI. Effect of parity on human chorionic gonadotropin levels and Down's syndrome screening. J Med Screen 1995;2:28.
55. Spencer K. The influence of gravidity on Down's syndrome screening with free beta hCG. Prenat Diagn 1995;15:87.
56. Lantz ME, O'Brien WF, Williams MC. The effect of sample preparation and storage on maternal triple-marker screening. Obstet Gynecol 1995;85:919.
57. Tew BJ, Payne H, Lawrence KM. Must a family with a handicapped child be a handicapped family ? Dev Med Chil Neurol 1974;16:95.
58. Tew BJ, Lawrence KM, Payne H et al. Marital stability following the birth of a child with spina bifida. Br J Psychiatry 1977;131:79.
59. Breslau N, Salkever D, Staurch KS. Women's labor force activity and responsabilities for disabled dependents: A study of families with disabled children. J Health Soc Behav 1982; 23:169.
60. Brambati B, Tului E, Bonacchi I, et al. Serum PAPP-A and free beta-hCG are first-trimester screening markers for Down syndrome. Prenat Diagn 1994;14:1043.
61. Spencer K, Aitken DA, Crossley JA et al. First trimester biochemical screening for trisomy 21: The role of free beta hCG, alpha fetoprotein and pregnancy associated plasma protein A. Ann Clin Biochem 1994;31:447.
62. Biagiotti R, Cariati E, Brizzi L et al. Maternal serum screening for Down's syndrome in the first trimester of pregnancy. Br J Obstet Gynaecol 1995;102:660.
63. Krantz DA, Larsen JW, Buchanan PD et al. First-trimester Down syndrome screening: free beta-human chorionic gonadotropin, and pregnancy-associated plasma protein A. Am J Obstet Gynecol 1996;174:612.
64. Wald NJ, George L, Smith D et al. Serum screening for Down's syndrome between 8 and 14 weeks of pregnancy. International Prenatal Screening Research Group. Br J Obstet Gynaecol 1996;103:407.
65. Wallace EM, Swanston IA, McNeilly AS et al. Second trimester screening for Down's syndrome using maternal serum dimeric inhibin A. Clin Endocrinol Oxf 1996;44:17.
66. Aitken DA, Wallace EM, Crossley JA et al. Dimeric inhibin A as a marker for Down's syndrome in early pregnancy. N Engl J Med 1996;334:1231.
67. Wald NJ, Densem JW, George L et al. Prenatal screening for Down's syndrome using inhibin-A as a serum marker. Prenat Diagn 1996;16:143.